Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...
April 10, 2024 07:00 ET | Source: Sitryx Therapeutics

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...